瑞舒伐他汀治疗老年稳定型冠心病的临床研究

Rosuvastatin Treatment of Elderly Patients with Stable Coronary Artery Disease Clinical Research

目的研究剂量不同瑞舒伐他汀治疗老年稳定型冠心病(SCHD)的临床疗效。方法选择2013年1月—2015年12月该院收治的老年SCHD患者98例,随机分为大剂量组与小剂量组各49例。大剂量组以常规药物+瑞舒伐他汀40 mg/d治疗,小剂量组常规药物+瑞舒伐他汀10 mg/d治疗。观察治疗前后两组血脂水平、临床疗效及不良反应。结果治疗后,大剂量组TC(4.76±0.67)、TG(1.65±0.32)、LDL-C(2.52±0.44)水平低于小剂量组TC(5.50±0.79)、TG(1.93±0.43)、LDL-C(0.84±0.13)水平,HDL-C(0.96±0.16)高于小剂量组HDL-C(3.08±0.54),总有效率(84.00%)高于小剂量组(60.00%),不良反应率(4.08%)低于小剂量组(22.45%),差异有统计学意义(P<0.05);结论大瑞舒伐他汀治疗SCHD疗效显著,不良反应率低。

Objective To study the doses, Shui-Shu simvastatin in treating senile patients with stable coronary artery disease（SCHD） clinical efficacy. Methods January 2013—December 2015 SCHD of elderly patients admitted to hospital in 98 cases, randomly divided into high-dose and low-dose groups in 49 cases.High dose of conventional drugs ＋Shui Shu simvastatin 40mg/d treatment, small doses of conventional drugs ＋ Shui Shu simvastatin 10mg/d treatment.Before and after treatment, two sets of blood lipid levels, clinical efficacy and adverse reaction. Results After treatment,the high-dose groups TC（4.76±0.67）、TG（1.65±0.32）、LDL-C（2.52±0.44）levels lower than the low-dose group（5.50±0.79）、TG（1.93±0.43）、LDL-C（0.84±0.13）, HDL-C（0.96±0.16）higher than the low-dose group HDL-C（3.08±0.54）,the total efficiency（84%） than in the low-dose group（60%）, adverse reactions（4.08%） is less than the low-dose group（22.45%）, a statistically significant（P〈0.05）. Conclusion Daruishu SCHD simvastatin treatment effect, low rate of adverse reactions.